Adaptimmune Therapeutics PLC Form 3 January 04, 2016 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| 1. Name and Address of Reporting Person <u>*</u> Amado Rafael | | Statement (Month/Day/Year) | | 3. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP] | | | | |
|---|----------------------|-------------------------------|---|--|--|--|--|---|
| (Last) (Fi | rst) (| (Middle) | 01/01/2016 | | 4. Relationship of Reporting Person(s) to Issuer | | 5. If Amendment, Date Original Filed(Month/Day/Year) | |
| 5 ASHWOOD L | ANE | | | | | | | |
| (Str | reet) | | | | (Check | all applicable) | | 6. Individual or Joint/Group |
| MALVERN, P | AÂ 1943 | 36 | | | .e | <pre>10% (Other v) (specify belo fedical Officer</pre> | ow) | Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person |
| (City) (Sta | ate) | (Zip) | | Table I - N | lon-Derivat | ive Securiti | es Be | neficially Owned |
| 1.Title of Security (Instr. 4) | | | | 2. Amount of Beneficially (Instr. 4) | | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nat Owne (Instr. | 1 |
| Ordinary Shares GBP0.001 per sh | | ominal va | lue of | 96,000 | | D | Â | |
| Reminder: Report on owned directly or inc | - | e line for eac | ch class of secu | irities benefici | ally S | EC 1473 (7-02 |) | |
| | informat required | tion conta to respoi | oond to the c ined in this f nd unless the IB control nu | orm are not e form displa | | | | |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security | 2. Date Exercisable and | 3. Title and Amount of | 4. | 5. | 6. Nature of Indirect |
|---------------------------------|-------------------------|------------------------|-------------|------------|-----------------------|
| (Instr. 4) | Expiration Date | Securities Underlying | Conversion | Ownership | Beneficial |
| | (Month/Day/Year) | Derivative Security | or Exercise | Form of | Ownership |
| | | (Instr. 4) | Price of | Derivative | (Instr. 5) |
| | | m'.1 | Derivative | Security: | |
| | | Title | Security | Direct (D) | |

OMB APPROVAL

Estimated average burden hours per

3235-0104

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Edgar Filing: Adaptimmune Therapeutics PLC - Form 3

| | Date Exercisable | Expiration Date | | Amount or Number of Shares | | or Indirect (I) (Instr. 5) | |
|-----------------------------------|---------------------|--------------------|--------------------|----------------------------------|--------------------|----------------------------------|---|
| tion to purchase linary Shares | (2) | 03/16/2025 | Ordinary Shares | 3,600,000 | \$ 0.74 <u>(3)</u> | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | |
|---|---------------|-----------|-----------------------------|-------|--|--|
| , or the second s | Director | 10% Owner | Officer | Other | | |
| Amado Rafael 5 ASHWOOD LANE MALVERN, PA 19436 | Â | Â | Chief Medical Officer | Â | | |

Signatures

Opti Ord

| /s/ Rafael Amado Name: Rafael | 01/04/2016 |
|-------------------------------|------------|
| Amado | 01/04/2010 |

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represented by 16,000 American Depositary Shares ("ADSs") held by Dr. Amado. Dr. Amado holds these Ordinary Shares in the form of ADSs. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc.
- (2) Will be exercisable as to 900,000 Ordinary Shares on March 16, 2016 and will be exercisable as to the remainder ratably in monthly installments on the sixtheenth of each month from April 16, 2016 through March 16, 2019.
- The exercise price was converted from GBP0.50 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S.
- (3) dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.